Unexplained Liver Damage, Cryptogenic Liver Cirrhosis, and Steatohepatitis May Be Caused by Latent Chronic Toxoplasmosis

Joseph Prandota

Joseph Prandota, MD, PhD, Emeritus Professor of Pediatrics & Clinical Pharmacology, Former Senior Fulbright-Hays Program and The Kosciuszko Foundation (twice) fellow, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland; 5 Bartla Str., 51-618 Wroclaw, Poland, and Faculty of Health Sciences and Physical Culture, The Witelon University of Applied Sciences, Legnica, Poland

Conflict-of-interest statement: The authors declare that there is no conflict of interest regarding the publication of this paper.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Joseph Prandota, MD, PhD, Faculty of Health Sciences, Wroclaw Medical University, 5 Bartla Street, 51-618 Wroclaw, Poland.

Email: jozef.prandota@umed.wroc.pl
Telephone: +48-71-348-42-10
Fax: +48-71-343-20-86

Received: March 26, 2019
Revised: April 2, 2019
Accepted: April 3, 2019
Published online: April 21, 2019

ABSTRACT

*T. gondii* is a globally distributed intracellular protozoan parasite affecting approximately 5-90% of human population and causing a variety of so far neglected diseases and clinical entities in both immunocompromised and immunocompetent individuals. Acute infection of the parasite in mice caused marked reduction in serum butyrylcholinesterase (BChE) activity and liver damage. BChE and acetylcholinesterase (AChE) are biomarkers of low-grade systemic inflammation and earlier it was suggested that the elevation of these two bioparameters may predict development of type 2 diabetes mellitus and Alzheimer’s disease. Serum BChE activity was found to be associated with overweight, obesity, and body fat distribution parameters. Recently, a positive association between *T. gondii* seropositivity and obesity has also been reported. Infection with the parasite was linked with the increase in the number of hepatic stellate cells known to play an important role in the development of fibrosis and its advancement to cirrhosis of any etiology. Moreover, several authors suggested that hepatitis with a clinical picture resembling acute viral hepatitis result from *T. gondii* infection. Abnormalities associated with cryptogenic liver cirrhosis markedly affect acquired immunity of the host and probably participate in triggering and persistence of several autoimmune diseases, especially that anti-*T. gondii* IgG antibodies have been found in the sera of both patients suffering from these clinical entities and in healthy individuals. Oxidative stress and immunosuppression due to the infection play an important role in these processes. It should be also noted that mammalian as well as the parasite cells, express two cholesteryl ester-synthesizing enzymes, ACAT1 and ACAT2, which share 44-47% of amino acid homology. ACAT1 is present in various cells and tissues, while ACAT2 expression is restricted to hepatocytes and intestinal mucosal cells. The parasite enzymes *TgACAT1* and *TgACAT2* localized to endoplasmic reticulum can synthesize and store abundant esters of cholesterol and triglycerides. The lifelong persistence and resulting surplus of ACAT1 and ACAT2, and *TgACAT1* and *TgACAT2* enzymatic activities especially in hepatocytes and/or intestinal cells of the host may therefore at least in part be responsible for development of steatohepatitis, and generation of ballooning hepatocytes, foamy macrophages, and clear cells (foamy) colitis. These abnormalities can be explained by the suppressed autophagy (it regulates lipid metabolism) in the liver due to proliferation of *T. gondii*. In alcoholic steatohepatitis, ballooning degeneration of hepatocytes may also at least partly result from the fact that ethanol dose-dependently stimulate microneme secretion in *T. gondii* tachyzoites and parasite attachment to the host cells, thus facilitating infection of the hepatic cells. The increased serum iron levels and hepatic iron overload reported in the patients with nonalcoholic hepatitis may be caused by the excess of NO produced by activated macrophages and hepatic cells of the host, as a defense molecule against infection with the parasite. NO intercepts iron before incorporation into ferritin and directly mobilizes iron from the serum protein in a glutathione-dependent manner. Finally, several reports provided data suggesting that the generation of Mallory-Denk bodies is linked with latent chronic hepatic toxoplasmosis, and...
T. gondii cathepsin L and B proteases play an important role in this process. These findings may be supported by the population-based studies demonstrating the link between infection with the parasite and development of liver abnormalities, and the increasing global burden of overweight and obesity in children and adults.

Key words: Toxoplasmosis; hepatic stellate cells; Butyrylcholinesterase; Cryptogenic liver cirrhosis; steatohepatitis; Hepatic fibrosis; Ballooned hepatocytes; Foamy cells; Mallory-Denk bodies; Cathepsin L and B proteases; Autoimmune hepatitis

© 2019 The Author(s). Published by ACT Publishing Group Ltd. All rights reserved.

Prandota J. Unexplained Liver Damage, Cryptogenic Liver Cirrhosis, and Steatohepatitis May Be Caused by Latent Chronic Toxoplasmosis. Journal of Gastroenterology and Hepatology Research 2019; 8(2): 2824-2840 Available from: URL: http://www.ghnet.org/index.php/jg/hr/article/view/2567

INTRODUCTION

T. gondii is the most prevalent chronic parasitic infection affecting about 6 billion people[1,2] and suspected to be a global health threat[3,4]. At present it is believed that the parasite causes asymptomatic infection in healthy persons, but severe clinical presentations can be found in congenital toxoplasmosis, ocular involvement, and in immunocompromised individuals, including patients with AIDS[5-8]. The purpose of this work was to present and analyze available literature data indicating a possible link between acute and chronic toxoplasmosis infection with the parasite and development of unexplained liver damage, cryptogenic liver cirrhosis, steatohepatitis, and several other hepatic histopathological abnormalities of unknown etiology.

LIVER DAMAGE

In animals, experimental T. gondii infection was associated with liver and kidney injury manifesting with a significant increase in serum alanine (AlAT) and aspartate aminotransferase (AspAT) activities, blood urea nitrogen level, decreased serum albumin concentration and alkaline phosphatase activity, albumin to globulin ratio, and marked abnormalities in plasma triglyceride and cholesterol levels[9-10]. Histopathology and histochemistry studies showed liver cells degeneration which progressed from hydropic to fatty, and marked cellular infiltration (granulomata) around the blood vessels[11]; the reticuloendothelial cells, Kupffer cells and phagocytes exhibited increased alkaline phosphatase activity[12]. In mice, treatment with azithromycin (a macrolide antibiotic with antitoxoplasmatic effects[13-15]) caused normalization of serum AlAT and AspAT activities and improvement of total serum protein, albumin and globulin concentrations, and albumin/globulin ratio[16] (Tables 1-3).

It must be noted that acute T. gondii infection in mice caused marked reduction in serum BChE activity (p < 0.01) and liver damage, and positive significant correlations between BChE activity in serum and BChE activity in liver (r = 0.89)[16]. In addition, serum albumin concentrations were markedly decreased (Table 1), and previously it was reported that this biomarker is strongly correlated with BChE activity[17]. At necropsy, liver of the infected animals showed random necrosis foci combined with the presence of tachyzoites and cysts containing bradyzoites, as well as an increase in spleen size. These findings are very important because AChE and BChE are biomarkers of low-grade systemic inflammation[18,19], and it was suggested that the elevation of these two bioparameters may predict the development of type 2 diabetes mellitus and Alzheimer’s disease[20]. These proposed associations are in line with my previous reports suggesting an important role of T. gondii infection in development of these two clinical entities[21,22]. BChE also serves as a marker predicting the prognosis of diseases[23] because when the serum activity of the enzyme is low, a high-risk of death must be

Table 1 Serum markers of liver and kidney injury in BALB/c mice infected intraperitoneally with tachyzoites of T. gondii (RH strain) and examined after 5 days (acc. to Da Silva et al [9]; with own modification).

| Parameter                  | Group of animals          | Controls (n = 10) | Infected (n = 10) |
|----------------------------|---------------------------|------------------|------------------|
| AlAT (U/L)                 |                           | 35.21 ± 11.73    | 258.13 ± 84.37   |
| Alkaline phosphatase (U/L) |                           | 358.44 ± 120.12  | 190.87 ± 78.66   |
| Albumin (g/dL)             |                           | 2.21 ± 0.03      | 1.51 ± 0.08      |
| Total proteins (g/dL)      |                           | 5.80 ± 0.40      | 4.55 ± 0.44      |
| Urea (mg/dL)               |                           | 69.28 ± 5.10     | 100.12 ± 25.75   |
| Creatinine (mg/dL)         |                           | 9.26 ± 0.32      | 0.87 ± 0.24      |

Results represent means ± SD. *Statistically significant results compared with controls (p < 0.05). AlAT, alanine aminotransferase.

Table 2 Damage of liver function in mice intraperitoneally infected with 3 × 10⁵ T. gondii tachyzoites and treated with azithromycin (250 mg/kg/day for 3 days, p.o.) (acc. to Al-Kaysi et al [7]; with own modification).

| Group of animals | Total serum protein concn (g/dL) | Serum albumin concn (g/dL) | AlAT (U/L) | AspAT (U/L) | Serum globulin concn (g/dL) | A/G ratio |
|------------------|----------------------------------|-----------------------------|------------|-------------|----------------------------|-----------|
| Controls         | 7.42 ± 0.12                      | 4.86 ± 0.26                 | 9.6 ± 0.12 | 10.6 ± 0.26 | 2.56 ± 0.16                 | 1.89      |
| Infected and treated | 11.02 ± 0.06                    | 5.30 ± 0.30                 | 50.80 ± 0.30 | 7.22 ± 0.24 | 2.61 ± 0.12                 | 1.02 ± 0.04 |
| Not infected and treated | 11.01 ± 0.11                    | 4.88 ± 0.26                 | 9.2 ± 0.10 | 10.6 ± 0.26 | 2.56 ± 0.16                 | 1.96      |

The values are means ± SE. *Statistically significant differences between respective groups were calculated using ANOVA test at p < 0.05. A/G, serum albumin to globulin concentration ratio.

Table 3 Serum biochemical markers of liver and kidney damage in ewes and does with toxoplasmosis (positive serum IgM antibodies directed against T. gondii) (acc. to Mahboub et al [8]; with own modification).

| Bioparameters                          | Sheep (n = 20) | Ewes (n = 15) | Controls (n = 20) | Goats with T. gondii infection (n = 15) |
|----------------------------------------|---------------|--------------|------------------|---------------------------------------|
| Total protein (g/dL)                   | 4.20 ± 0.15   | 4.10 ± 0.37  | 5.44 ± 0.27      | 4.03 ± 0.80                           |
| Albumin (g/dL)                         | 1.81 ± 0.20   | 1.24 ± 0.13  | 2.15 ± 0.23      | 1.84 ± 0.34                           |
| Globulin (g/dL)                        | 2.39 ± 0.07   | 3.11 ± 0.29  | 3.47 ± 0.27      | 3.19 ± 0.63                           |
| A/G ratio                              | 0.85 ± 0.08   | 0.41 ± 0.08  | 0.72 ± 0.07      | 0.34 ± 0.23                           |
| AspAT (U/mL)                           | 58.87 ± 1.92  | 33 ± 2.69    | 67.23 ± 5.09     | 47.33 ± 3.56                          |
| AlAT (U/mL)                            | 15.11 ± 0.43  | 22.86 ± 1.99 | 15.07 ± 0.81     | 14.67 ± 2.04                          |
| BUN (mg/dL)                            | 24.35 ± 2.07  | 32.26 ± 2.26 | 42.50 ± 2.74     | 25.34 ± 5.64                          |
| Glucose (mg/dL)                        | 17.82 ± 1.28  | 51.49 ± 6.65 | 25.28 ± 2.53     | 20.38 ± 5.95                          |
| Cholesterol (mg/dL)                    | 41.61 ± 4.33  | 57.84 ± 5.17 | 84.15 ± 5.85     | 51.79 ± 17.80                         |
| CRP (mg/dL)                            | 8.40 ± 1.70   | 10.71 ± 2.48 | 12.12 ± 2.37     | 12.00 ± 8.49                          |

Results are means ± SE. *Statistically significant results compared with respective control values (p < 0.05). AspAT, aspartate aminotransferase; AlAT, alanine aminotransferase; BUN, blood urea nitrogen. CRP, C-reactive protein.

Prandota J. Toxoplasmosis causes liver damage and cirrhosis
Prandota J. Toxoplasmosis causes liver damage and cirrhosis taken into consideration\(^{[13,17]}\). The individuals with the lowest serum BChE activity had significantly higher mortality than those with the highest value\(^{[10]}\). In middle-aged and elderly men and women, Calderon-Margalit et al\(^{[10]}\) showed that serum BChE activity was inversely related to age and was positively correlated with the serum levels of albumin \((r = 0.35, p < 0.001)\), cholesterol \((r = 0.31, p < 0.001)\), and triglycerides \((r = 0.30, p < 0.001)\). Moreover, the enzyme activity was strongly associated with overweight, obesity, and body fat distribution parameters \((e.g., \text{body mass index}, r = 0.20, p < 0.001)\), and recently, a positive association between \(T. gondii\) seropositivity and obesity has been found\(^{[18]}\).

Cholinesterases are enzymes present in cholinergic and noncholinergic tissues, as well as in blood and other body fluids. The AChE is a membrane-bound enzyme mainly found in the brain, muscles, erythrocytes, lymphocytes, and cholinergic neurons\(^{[19,20]}\), while BChE is present in the intestine, liver, kidney, heart, lung, brain, and serum\(^{[21-22]}\). AChE inhibits activation of macrophages and release of proinflammatory cytokines, such as IL-6, TNF-\(\alpha\), IL-1, and IL-18\(^{[23]}\). In rats, \(T. gondii\) infection was associated with a significant increase in the activity of AChE in whole blood and lymphocytes, and a positive correlation was found between the enzyme activity and number of lymphocytes \((p < 0.01)^{[20]}\). The BChE is responsible for cholinergic neurotransmission\(^{[24]}\), immune responses\(^{[25]}\), cardiovascular risk and lipid metabolism\(^{[26]}\). Autonomic system dysfunctions, characterized by lower vagal and higher sympathetic tone have been documented in chronic inflammatory diseases and aging, associated certain level of systemic inflammation\(^{[25-28]}\). A correlation between higher vagal tone as determined by the increased frequency component of heart rate variability and lower proinflammatory cytokine levels has been reported\(^{[27,28]}\). Cholinergic modalities, acting through vagus nerve and/or q7 subunit-containing nicotinic acetylcholine receptor-mediated mechanisms have been shown to suppress excessive inflammation in several experimental models of disease\(^{[27]}\). In this context, numerous comorbidities frequently observed in the patients with autoimmune diseases, associated with viral and other infectious agents, including \(T. gondii\), may be at least in part explained by the liver damage caused by the parasite\(^{[29]}\). The hepatic injury probably establishes a favorable local tissue and systemic environment in the body that facilitates growth and proliferation of these infectious agents further intensified by the impaired cholinergic modulation of systemic inflammation. In addition, such patients are usually subjected to many invasive procedures, including endoscopy, surgery, dental care, otorhinolaryngologic investigation, and frequently receive intravenous medications, fluids, blood and/or its components, that all increase risk of viral, bacterial and/or parasite infections\(^{[29,30]}\).

Several authors reported that hepatitis with a clinical picture resembling acute viral hepatitis may result from \(T. gondii\) infection\(^{[31-33]}\). T cell function in patients with Australia antigen (AA)-associated hepatitis have shown that persistence of this antigen was associated with an increased production of various pro- and anti-inflammatory cytokines which are overlapping with \(T1\) and \(T2\) type of cytokines generated by \(T. gondii\) infection, such an excess of various factors and released biomediators may exert beneficial or harmful effects in the host, depending on their final constellations in the body. These suggestions are in agreement with recent reports that emphasized an important role of the parasite in development of liver damage and \(T. gondii\)-related hepatitis\(^{[34-41]}\).

The above-presented data suggest that liver damage caused by latent chronic \(T. gondii\) infection has an important impact on the innate and acquired immunity of the host, development of various comorbidities and their clinical course, and finally on improvement/worsening of the host’s health. The seroprevalence of anti- \(T. gondii\) IgG antibodies in various autoimmune diseases, including primary biliary cirrhosis have been presented in Tables 4 and 5. In these patients, impaired cellular immunity due to the infection with the parasite may also play an important role in triggering, development and persistence of these clinical entities\(^{[42]}\).

### CRYPTOGENIC LIVER CIRRHOSIS (CLC)

This chronic liver disease with so far not established particular etiology accounts for 5-30% of cases of cirrhosis and about 10% of liver transplants\(^{[43-45]}\). In Germany, presumed cryptogenic liver disease (probably an early phase of liver cirrhosis) was found to be associated with high prevalence of autoimmune-negative autoimmune hepatitis, low prevalence of nonsclerotic steatohepatitis (NASH), and no evidence for occult viral etiology\(^{[46]}\). At present, it is believed that the leading causes of CLC include previously unrecognized NASH, silent autoimmune hepatitis, occult

### Table 4 Serum IgG levels of anti-infectious agents antibodies more prevalent in primary biliary cirrhosis compared with controls (acc. to Shapiro et al\(^{[42]}\); with own modification)

| Infectious agent | Patients with primary biliary cirrhosis | Controls | \(P\) value |
|-----------------|----------------------------------------|----------|------------|
| \(T. gondii\) (IU/mL) | 35.4 ± 9.1 | 36.4 ± 7.6 | < 0.001 |
| EBV-EA AI | 1.7 ± 0.2 | 0.9 ± 0.2 | < 0.0001 |

\(AI\), antibody index. EBV-EA, Ebstein-Barr virus - early antigen. Results are given as mean ± SE. Anti-EBV-EA antibodies concentrations positively correlated with anti- \(T. gondii\) antibody levels in those patients \((Spearman correlation \(r = 0.35, p < 0.001)\). A similar positive correlation was detected in IBC patients against anti-EBV-EA and CMV antibodies levels \((r = 0.32, p < 0.01)\), which may suggest a secondary origin of their generation as compared with the primary and the same \(T. gondii\)-related IL-21 cytokine stimulus intensity required to control chronic viral infection\(^{[43-45]}\).

### Table 5 Prevalence of anti- \(T. gondii\) IgG antibodies in 1514 serum samples of patients with various autoimmune diseases (acc. to Shapiro et al\(^{[46]}\); with own modification)

| Disease/Clinical entity | Anti- \(T. gondii\) IgG positive | Geographical region | \(P\)-value |
|------------------------|-------------------------------|-------------------|------------|
| Antiphospholipid syndrome (APS) | 82/159 (52%) | Europe | < 0.0001 |
| Cryoglobulinemia \(^{b}\) | 65/117 (56%) | Europe | < 0.0001 |
| ANCA-associated vasculitis | 45/68 (66%) | Europe | < 0.01 |
| Autoimmune thyroid diseases | 69/120 (57%) | Europe | < 0.0001 |
| Systemic sclerosis | 46/80 (58%) | Europe | < 0.0001 |
| Rheumatoid arthritis | 27/35 (77%) | Europe | < 0.0001 |
| Rheumatoid arthritis | 55/152 (36%) | Latin America | NS |

\(^{b}\) Including primary and secondary APS; \(^{b}\) Including cryoglobulinemia and mixed cryoglobulinemia. \(^{\prime}\) \(P\) values for the comparison with matched healthy controls of the same geographical region. In addition, the following specific autoimmune diseases were associated with markedly increased serum anti- \(T. gondii\) IgG antibodies/autoantibodies: polymyositis\(^{[47]}\), rheumatoid arthritis\(^{[48-50]}\), Hashimoto’s and Graves’ diseases\(^{[51,52]}\), Crohn disease\(^{[53,54]}\), antiphospholipid syndrome\(^{[54]}\), Wegener’s granulomatosis and other vasculitides\(^{[55]}\), autoimmune bullous disease \([56]\), systemic lupus erythematosus\(^{[57]}\), diabetes mellitus type 1 and 2\(^{[58,59]}\), optical nerve and retinal diseases with visual loss \((the 22 kDa neuronal antigen found in the patients may represent \(T. gondii\) antigen\(^{[59-61]}\).

\(^{b}\) Including primary and secondary APS; \(^{b}\) Including cryoglobulinemia and mixed cryoglobulinemia. \(^{\prime}\) \(P\) values for the comparison with matched healthy controls of the same geographical region. In addition, the following specific autoimmune diseases were associated with markedly increased serum anti- \(T. gondii\) IgG antibodies/autoantibodies: polymyositis\(^{[47]}\), rheumatoid arthritis\(^{[48-50]}\), Hashimoto’s and Graves’ diseases\(^{[51,52]}\), Crohn disease\(^{[53,54]}\), antiphospholipid syndrome\(^{[54]}\), Wegener’s granulomatosis and other vasculitides\(^{[55]}\), autoimmune bullous disease \([56]\), systemic lupus erythematosus\(^{[57]}\), diabetes mellitus type 1 and 2\(^{[58,59]}\), optical nerve and retinal diseases with visual loss \((the 22 kDa neuronal antigen found in the patients may represent \(T. gondii\) antigen\(^{[59-61]}\).

\(^{b}\) Including primary and secondary APS; \(^{b}\) Including cryoglobulinemia and mixed cryoglobulinemia. \(^{\prime}\) \(P\) values for the comparison with matched healthy controls of the same geographical region. In addition, the following specific autoimmune diseases were associated with markedly increased serum anti- \(T. gondii\) IgG antibodies/autoantibodies: polymyositis\(^{[47]}\), rheumatoid arthritis\(^{[48-50]}\), Hashimoto’s and Graves’ diseases\(^{[51,52]}\), Crohn disease\(^{[53,54]}\), antiphospholipid syndrome\(^{[54]}\), Wegener’s granulomatosis and other vasculitides\(^{[55]}\), autoimmune bullous disease \([56]\), systemic lupus erythematosus\(^{[57]}\), diabetes mellitus type 1 and 2\(^{[58,59]}\), optical nerve and retinal diseases with visual loss \((the 22 kDa neuronal antigen found in the patients may represent \(T. gondii\) antigen\(^{[59-61]}\).
non-B, non-C viral hepatitis (hepatitis X), and occult past ethanol exposure. Leite et al. reported that in their 47 patients with CLC, the following prevalences were demonstrated: impaired fasting glycemia (68%), low HDL levels (58.1%), total hypercholesterolemia (27.9%), hypertriglyceridemia (16.3%), and obesity (27.5%). The results obtained in the patients with CLC showed statistical similarity with the data of the NASH group regarding fasting glycemia (62.8%) and HDL levels (53.8%, males) of 031. Caldwell et al. found that among their 70 consecutive patients with cryptogenic cirrhosis, both diabetes type 2 and obesity (73% of individuals) were significantly more common compared with the cirrhotic patients with primary biliary cirrhosis or hepatitis C. It must be noted that among 567 patients with chronic liver disease evaluated by Kodali et al., 28 individuals (4.9%) had no established a definite etiology, and nearly half of the patients with presumed CLC (13 of them, 46%) had a history of previous blood transfusion, thus supporting the hypothesis of a non-A, non-B, and non-C hepatitis virus. This may suggest that latent T. gondii infection associated with blood transfusion plays at least in part an important role in development of cryptogenic liver disease, and support the indication of several authors for screening blood donors for serum AIAT as well as T. gondii IgG activities to reduce posttransfusion hepatitis. Moreover, it was found that the infection with the parasite significantly affected glycolysis, gluconeogenesis and tricarboxylic acid cycle metabolic processes, and probably was responsible for development of type 1 and 2 diabetes, and obesity. These findings are therefore well in line with the suggestion that cryptogenic liver disease in children represents a novel congenital disorder of glycosylation.

In a study of 354 patients with unexplained abnormal liver function tests and in the absence of diagnostic serology, liver biopsy showed some degree of fibrosis in 26% of individuals, and 6% were cirrhotic. Thirty four and 32% of biopsies suggested NASH or fatty liver, respectively. Other diagnoses included cryptogenic hepatitis, drug toxicity, secondary biliary cirrhosis, and autoimmune hepatitis. NASH was considered the commonest cause of cryptogenic cirrhosis, associated with diabetes and obesity in some individuals. In two other studies, cirrhosis of unknown etiology was found in 3-30% of individuals hospitalized because of this clinical entity. The so-called residual histological findings, such as foci of autoimmune-like inflammatory infiltrates versus NASH-like foci of steatosis, cellular ballooning, and glycogenated nuclei may finally help in defining the underlying cause of cryptogenic cirrhosis.

Interestingly, subclinical liver involvement is frequent in systemic lupus erythematosus (SLE), Coldhammer et al. identified 40 SLE patients with liver enzyme abnormalities, and biopsies performed in 20 individuals showed changes characteristic for nonalcoholic fatty liver disease (n = 8), autoimmune hepatitis (6), primary biliary cirrhosis (3), hepatitis C (3), and cryptogenic cirrhosis (2). Systemic sclerosis (SSc) is another autoimmune disease characterized by vascular obliteration, excessive extracellular matrix deposition, and fibrosis of the connective tissues of the skin, lung, gastrointestinal tract, heart, and kidneys. Endothelial cell dysfunction and damage represent one of the first disturbances in the pathogenesis of SSc, and chronic inflammation plays an important role in the development of atherosclerotic plaques. A 60-kDa protein belonging to the heat shock proteins (HSPs) was suggested to be involved in the pathomechanism of these abnormalities. It was demonstrated that Hsp60 bound lipopolysaccharide (LPS) tightly and it was the Hsp60-bound LPS, not Hsp60 itself, that was responsible for the observed cytokine effects of Hsp60 preparations. In addition, Hsp60-bound LPS was more potent than LPS alone in inducing cytokine production. It must be noted that T. gondii HSPs, particularly Hsp60 and Hsp70 (Hsp70 provides cellular protection against oxidative stress and functions as a B cell mitogen) released mainly during bradyzoite transition are highly immunogenic, capable of inducing antibody production and T-cell activation. Each of these HSPs was found to bound a distinct set of peptides, including antigen peptides and its precursors, and various HSPs have different efficiency to activate monocytes and dendritic cells, as well as to release NF-κB, NO and other pro- and antiinflammatory cytokines. Specifically, Hsp60 exerted immune stimulatory effects on vascular endothelium (upregulation of adhesion molecules), smooth muscle cells (IL-6) and monocyte/macrophages inducing NO, IL-6, IL-12 and TNF-α production, dendritic cells (IL-1β, IL-6, IL-12, TNF-α maturation), B cells (proliferation, IL-6, IL-10, upregulation of MHCII, CD69, CD40, CD86), and keratinocytes. In this context, it should be emphasized that the proteins with molecular weights of 58 and 60 kDa have been demonstrated amongst excretory/secretory protein antigens released from purified tachyzoites/bradyzoites of T. gondii and various components of the parasite in samples of human and animal sera.

Tweezer-Zaks et al. found nine patients with cryptogenic cirrhosis comprising 0.15% of the familial Mediterranean fever (FMF) patient population. This rate was significantly higher than the rate of 0.015% of cirrhosis of all types expected in the total population of Israel (p < 0.000). FMF is a disorder presenting in childhood or adolescence with 1- to 3-day episodes of fever often accompanied by severe abdominal pain, pleurisy, monoaortic arthritis, or an erythematous rash on the ankle or foot known as erysipelas erythema. Importantly, targeted disruption of pyrin, the FMF protein, caused heightened sensitivity to endotoxin and a defect in macrophage apoptosis. In addition, pyrin appeared to have both inhibitory and potentiating effects on IL-1β production and played a role in regulating NF-κB activation and apoptosis. It was suggested that in patients with FMF T. gondii infection plays an important role in the pathogenesis of Mollaret meningitis. Moreover, in human astrogliosis cells and in murine mast cells infected with T. gondii tachyzoites, the parasite induced upregulation of profibrotic factors, such as matrix metalloproteinase-2 and -9 (MMPs) via Erk1/2-NF-κB pathway, and MMPs are a family of the extracellular matrix-degrading enzymes that are generally synthesized and secreted as latent soluble enzymes requiring activation in the extracellular space.

In summary, these data suggest that latent chronic T. gondii infection may be responsible for development of CLC. Abnormalities associated with CLC markedly affect acquired immunity of the host and probably participate in triggering and maintaining several autoimmune diseases, especially that anti-T. gondii IgG antibodies have been found in the sera of both patients suffering from many of these clinical entities and in healthy individuals, which is in line with a cosmopolitan distribution of the pathogen.

**MOLECULAR PATHOBIOLOGY OF HEPATIC TIBROSIS**

Chronic inflammatory response is sometimes associated with the accumulation of extracellular matrix components including collagens, fibronectin and hyaluronic acid, and numerous fibrotic diseases affecting the liver, lung, skin, heart, and kidney, are believed to have an infectious etiology with bacteria, viruses, T. gondii, and fungi. Also, hepatic fibrosis may be associated with autoimmune liver disorders, including autoimmune hepatitis, primary biliary cirrhosis.
or primary sclerosing cholangitis. Chemokines, such as for example, a profibrotic factor CXCL 10, promote hepatic inflammation and liver cirrhosis by prevention of NK cell mediated hepatic stellate cells (HSCs) inactivation, because the cytokine is responsible for the recruitment and localization of inflammatory cells to sites of tissue damage or infection[122]. It must be noted that HSCs secrete CXCL 10 when stimulated with IFN-γ[122], and during T. gondii infection the cell numbers markedly increased[46]. Moreover, Furtado et al[116] found that human monocyte-derived dendritic cells infected with T. gondii tachyzoites transmigrated in larger numbers across stimulated human retinal endothelium than noninfected dendritic cells (p < 0.004). Antibody blockade of ICAM-1, VCAM-1, and activated leucocyte cell adhesion molecule inhibited transmigration, while chemokines CCL21 or CXCL 10 increased this process[113].

Ustun et al[114] investigated etiology of liver cirrhosis and frequency of T. gondii seroprevalence in 108 patients and found that toxoplasma IgG and IgM seropositivity was present in 74 (68.5%) individuals compared with 24 (48%) of 50 participants in the control group (p < 0.05) (Tables 6 and 7). A case-control epidemiological study demonstrated a link between T. gondii infection with liver cirrhosis[39], Atmaca et al[40] showed that infection with the parasite in mice was associated with the increase in the number of HSCs. The number of these cells was highest on day 6 after inoculation of animals as compared with the numbers found on days 4 and 2 after inoculation, and in controls (all p < 0.05). There was also a significant relationship between the number of GFAP-positive HSCs when they were compared with T. gondii antigen immunostaining (p < 0.05), and the amount of immunostaining markedly increased with the increase in the number of HSCs[40].

Table 6 Etiology of liver cirrhosis in 108 analyzed patients (acc. to Ustun et al[114]; with own modification).

| Etiology of liver cirrhosis | Number of patients | % |
|-----------------------------|--------------------|---|
| Hepatitis B                 | 37                 | 34.3 |
| Hepatitis C                 | 27                 | 25 |
| Alcoholic cirrhosis         | 18                 | 16.7 |
| Primary biliary cirrhosis   | 12                 | 11.1 |
| Unknown etiology            | 9                  | 8.3 |
| Autoimmune hepatitis        | 5                  | 4.6 |

Table 7 Seroprevalence of T. gondii IgG and IgM in patients with liver cirrhosis (acc. to Ustun et al[114]; with own modification).

| No of pts | Age (yrs) | Sex (M/F) | IFAT and ELISA IgG/+(%) | IFAT and ELISA IgM+(%) | Active disease significant with respect to IgG(+) | IgM(+) |
|-----------|-----------|-----------|-------------------------|------------------------|-----------------------------------------------|--------|
| Liver cirrhosis | 108 | 51.5 ± 10.2 | 58/70 | 74 (68.5%) * | 2 | 31 (28.7%) * | 2 (1.85%) |
| Controls   | 50 | 40 ± 6.7 | 19/31 | 24 (48%) | 0 | 4 (8%) | 0 |

Results represent means ± SD. *Statistically significant results compared with controls.

Table 8 Virulent T. gondii RH strain antigen expression in the hepatic stellate cells (HSCs) of Swiss albino mice infected intraperitoneally with 10⁶ tachyzoites and examined 2, 4, and 6 days after inoculation (DAI) (acc. to Atmaca et al[40]; with own modification).

| Antibody | Controls (n = 5) | 2 DAI (n = 5) | 4 DAI (n = 5) | 6 DAI (n = 5) | P |
|----------|-----------------|---------------|---------------|---------------|---|
| No of GFAP-positive HSCs | 0.902 ± 0.080 | 2.515 ± 0.383 | 3.090 ± 0.171 | 3.609 ± 0.316 | < 0.05 |
| Amount of anti-T. gondii antigen immunostaining | 3.538 ± 0.440 | 4.136 ± 0.218 | 4.632 ± 0.337 | < 0.05 |

Results represent means ± SD; n, number of animals. GFAP, glial fibrillary acidic protein. The Mann-Whitney U-test was used to compare GFAP-immunoreactive cells and anti-T. gondii-immunopositive areas in the liver between the parasite-infected groups and controls. The relationship between HSCs and the parasite antigens were assessed using the Kruskal-Wallis test.
the intracellular growth of *T. gondii* in vitro in human pulmonary fibroblasts showed that tachyzoites of the parasite induced activation of human platelets, and PDGF mediated inhibition of the intracelluar growth in a virulent *T. gondii* strain[131]. It was found that human platelet to the parasite ratios as low as 1:3 were toxic to the protozoan with distinct cell-cell contact essential for platelet-mediated cytoxicity[132]. Adherence of platelets to *T. gondii* and disruption of surface membranes and cytoplasmic contents of the organisms were documented ultrastructurally[134]. Thromboxane (TX) played an important role in these processes because both the TXA2-generating platelet microsome system and a stable TXA2 analog-induced damage to the cellular membranes of the parasite, as noted by transmission electron microscopy[136]. Recently, Hendersen et al[137] showed that *T. gondii*-stimulated platelets released oxygenated products of both (13-hydroxyoctadecadionoic acid (no acid - 12.3%), that also may be of importance for the cytotoxic host defense response against infection with the parasite.

**8ALLOOED HEPATOCYTES AND MALLORY-DENK BODIES (MDBs)**

Hepatocellular “ballooning” is an important histological hallmark of liver pathology found particularly in steatohepatitis manifested by degeneration of hepatocytes associated with enlargement, swelling, rounding, and characteristic reticulated cytoplasm[138,139].

These changes in hepatocyte morphology may be observed also in many other acute and chronic liver diseases, including autoimmune hepatitis, neonatal giant hepatitis, acute viral hepatitis, both alcoholic and nonalcoholic steatohepatitis, and ischemia/reperfusion injury of liver allografts[139-141]. The intermediate keratin filaments (IF) play an important role in the stabilization and topographical localization of a cell and its organelles, and a pronounced diminution or even less of keratin 8/18 was found in the IF cytoskeleton of ballooned hepatocytes[139].

MDBs are an intracellular deposition of misfolded proteins (keratins, chaperones Hsp90 and 25 families, α-B crystallin, phosphoepitopes/kinases, protein degradation machinery, and others, such as ubiquitin, tubulin, as well as intracytoplasmic hyaline inclusions, glycogen bodies, ground glass inclusions (hallmarks of chronic HBV infection reflecting hypertrophic endoplasmic reticulum), pale bodies, α-antitrypsin inclusions and megamitochondria[142]. Sometimes MDBs appear as numerous small globular structures distributed throughout the cytoplasm, near nucleus, or localized at the cell periphery (early MDBS = small cytoplasmic globular structures; mature MDBS = large paranuclear inclusions; old MDBS = involution stage present at the cell periphery)[142]. Interestingly, IF cytoskeleton damage was shown to result from oxidative stress in various human liver diseases and in the mouse models of steatohepatitis[142-144]. It seems that *T. gondii* infection may be at least partly responsible for development of these abnormalities because Yang et al[144] showed that in mice injected intraperitoneally with 2.5 x 10^6 *T. gondii* tachyzoites, the serum level of the oxygen free radicals (NO, "OH, O") increased along with the days of infection, and superoxide dismutase concentration reached a peak on the 3rd day of the investigation. In asymptomatic *T. gondii*-seropositive blood donors oxidative stress and immunosuppression also have been demonstrated[145-147]. Moreover, it was found that oxidative stress with markedly increased serum malondialdehyde and decreased glutathione levels is characteristic for *T. gondii* seropositive patients[148,149] and chickens orally infected with tissue cysts of the protozoan[150] (Tables 10 and 11).

Hepatic steatosis is caused by the abnormal accumulation of predominantly triglycerides in the liver[140]. Histological examinations of liver parenchyma revealed presence of triglyceride droplets in the cytoplasm of hepatocytes and their accumulation in small and large vesicles which impairs liver function and makes this organ more susceptible to other injuries[140]. Immunochemical analysis of steatohepatitis performed by Lackner et al[140] showed that in macrovesicular steatosis the IF cytoskeleton was only pushed to the cell periphery by the accumulated triglycerides, as it was also observed in all their cases of steatosis. In alcoholic steatohepatitis, ballooning degeneration of hepatocytes can at least partly be explained by the finding that ethanol and its metabolite acetaldehyde elevated intracellular concentration of Ca^2+ by mobilizing the ion from intracellular stores[149]. Moreover, ethanol dose-dependently stimulated microneme secretion in *T. gondii* tachyzoites and parasite apical attachment to host cells, thus facilitating infection of hepatic cells[149]. Ethanol is known to have several targets in a variety of vertebrate cells by affecting signal transduction[150], such as for example activation of phosphatidylinositol-specific phospholipase C in hepatocytes[151], and triggered amylase secretion from pancreatic acini by increasing Ca^2+ levels[152], and therefore together with oxidative stress could be the cause of marked disturbances in function and morphology of the host cells. Furthermore, liver microsomal fatty acid oxidizing enzymes, such as cytochrome P450 CYP2E1 expression are increased in both alcoholic fatty liver disease (AFLD) and nonalcoholic fatty liver disease (NAFLD). Since CYP2E1 also metabolizes ethanol[153], fatty acid-related induction of this enzyme contributes to generation of acetaldehyde, which forms immunogenic adducts[154] with various intra- and extracellular biomolecules and exacerbates reactive oxygen species production in AFLD[155]. In this context, the prevalence of non-organ-specific autoantibodies (NOSAs) and chronic liver disease in general population[156,157], NOSAs as the hallmark of a subclinical autoimmune disease[158,159,160], the exacerbation of autoimmune chronic hepatitis by interferon therapy[160], the presence of autoantibodies to cytoskeletal filaments, actin and intermediate filaments in chronic active hepatitis[161], as well as the evidence against hepatitis viruses as important causes of chronic liver diseases[162].

**Table 10** Levels of malondialdehyde (MDA) and glutathione (GSH) in aorta and heart of broiler chickens infected intraperitoneally with 50 T. gondii (acc. to Al-Kennany[147]; with own modification).

| Groups | MDA (μmol per gm wet tissue) | GSH (μmol per gm wet tissue) |
|--------|-----------------------------|-----------------------------|
| Aorta  | 125 ± 1.05                  | 0.622 ± 0.022 *             |
| Heart  | 105 ± 0.33                  | 0.773 ± 0.026               |
| Infected | 529.8 ± 2.32 *             | 0.273 ± 0.01                |

Results are expressed as means ± SD of 10 broiler chickens per group. *Significant differences at p ≤ 0.05.

**Table 11** Serum glutathione, malondialdehyde, and NO concentrations in *T. gondii*-seropositive patients and healthy controls (acc. to Karaman et al[69], with own modification).

| Bioparameter | Group | No of participants | Serum levels (mean ± SD) | P values |
|--------------|-------|--------------------|--------------------------|----------|
| Glutathione  | Patients | 37                | 3.96 ± 0.10             | 0.001    |
|              | Controls | 40                | 10.37 ± 0.13            |          |
| Malondialdehyde | Patients | 37                  | 41.32 ± 2.05            | 0.001    |
|              | Controls | 40                  | 9.18 ± 1.21             |          |
| NO           | Patients | 37                | 47.47 ± 1.08            | 0.001    |
|              | Controls | 40                | 59.18 ± 1.29            |          |

Serum glutathione and NO levels are expressed as μmol/L, and malondialdehyde concentrations represent nmol/L. Results statistically significant at p < 0.05.
of autoimmune hepatitis[161], are all well in line with worldwide dissemination of the parasite and modulation of the host cell proteome by the intracellular pathogen (e.g. cytoskeleton-associated protein 4, actin filament, actin beta, actin gamma 1 propeptide, actinin-1 alpha, etc.[176]). A similar profuse generation of antibodies and autoantibodies directed against brain proteins in patients with autism and their families probably associated with *T. gondii* infection[165] also seems to further support the above-presented reasoning.

Studies in animals showed that oral infection with *T. gondii* resulted in different quantitative and morphological changes in myentric plexus neurons. For instance, in rats no changes in the population or density of these cells were observed[162,163], while there was an intense myentric plexus neuronal cells death and atrophy reported in chicken[164]. On the other hand, in pigs orally infected for 30 days with oocysts of *T. gondii III* (M7741 strain) Odorizzi et al.[165] showed that the number of nitrergic NADPHd-p neurons per ganglion markedly increased, and the cells became hypertrophic through the augmentation of the cell body by 12.8% (*p* < 0.0001), and specifically through the increase of the nuclear area by 24.8% (*p* < 0.0001) (no change was observed in the distribution among different classes of neuronal cell size) (Tables 12 and 13). Because NO play an important role in resistance of the host cells against *T. gondii* infection[166,167], it was suggested[165] that the cell hypertrophy may be indicative of the increased generation of biochemical mediator(s) with antiparastic activity that may simultaneously exert a detrimental effect on the tissue cells containing parasites[164,165]. This reasoning is in line with the above argumentation that the oxidative stress associated with *T. gondii* infection play an important role in development of disturbances of the host cell morphology.

Finally, one may suggest that MDBs and the intracellular hyaline bodies observed in neoplastic and nonneoplastic hepatocyes[162-164] are linked with latent chronic intracellular *T. gondii* infection. These peculiar abnormalities probably represent the remnants of tachyzoites/bradyzoites/sporozoites/oocysts, such as example amylopectin, lipid droplets, PV membranes, etc., biotransformed by changing (especially acidic) pH of the inflamed liver tissue and various enzymes of both the host cell and the parasite itself, like it was suggested for the amyloid plaques produced in the brain cells of patients with Alzheimer’s disease[166]. Interestingly, Mayer et al.[166] also suggested that MDBs resemble inclusion bodies associated with chronic neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.

### STEATOHEPATITIS

*T. gondii* is a sterol-auxotrophic organism incapable of sterol synthesis and therefore scavenge cholesterol from mammalian host cells[170]. Similarly as in mammalian cells, most of this lipid is concentrated at the plasma membrane of the parasite[217]. Cholesterol is a vital part of membranes but its overabundance in cells leads to inflammation and oxidative damage[179]. Mammalian cells as well as the parasite, express two cholesterol ester (CE)-synthesizing enzymes, ACAT1 and ACAT2, which share 44-47% of amino acid homology[170,172]. ACAT1 is a ubiquitous and is responsible for CE formation in brain, adrenal glands, macrophages, and kidneys, while ACAT2 is expressed in the hepatocyte as the major cholesterol esterifying enzyme in human liver[171] and in the small intestine villi[174]. Free cholesterol (a toxic polar lipid) is also esterified by ACAT2 to CEs (nonpolar compounds)[172]. ACAT2 plays a pivotal role in dietary cholesterol absorption[171]. In mammalian cells, the main stored neutral lipids are triacylglycerol and CEs, which are produced by two related enzymes, acyl-CoA: diacylglycerol acyltransferase (DGAT) and acyl-CoA: cholesterol acyltransferase (ACAT), respectively, and both can contribute to membrane biogenesis[176,177]. Both enzymes ACAT1 and ACAT2 utilize cholesterol or oxysterols but different acyl-CoA (ACAT1 - 20:4; ACAT2 - 16:0,18:1 18:2) [176].

*T. gondii* enzymes also can synthesize and store both esters of cholesterol (TgACAT1 and TgACAT2) [176,177] and triglycerides (TgDGAT1) [179].

Cholesteryl oleate C18:1 (42%) and palmitate C16:0 (26%) are the main esters in mammalian cells, but the parasite also has uniquely large amounts of cholesteryl eicosanote C20:1 (7%), and lesser amounts of cholesteryl palmitoleate C16:1, steaerate C18:0, linoleate C18:2, arachidionate C20:4, and some polysaturated C22 fatty acids[170]. It should be noted that both these enzymes (ACAT1 and ACAT2) are endoplasmic reticulum (ER)-resident proteins. Interestingly, the MDBs were reported to contain ground glass inclusions described as the hallmarks of chronic HBV infection reflecting hypertrophic ER[142], whereas ACAT2 produced CEs that were assembled just in the ER[171]. One cannot therefore exclude that CEs accumulated in the hypertrophic ER of the patients with HBV infection[142], at least in part were the result of abundant TgACAT2 activity in the hepatic cells of those individuals who had a concomitant subclinical *T. gondii* infection.

The fact that mammalian ACAT2 expression is restricted to hepatocytes and intestinal mucosal cells[170,174], is very important because it strongly supports our earlier suggestion that peroral *T. gondii* infection plays an active role in the pathogenesis of “clear cell” colitis with foamy macrophages present in intestinal tissues[175]. Moreover, the ACAT expression in the hepatocytes probably is also involved in the development of nonalcoholic steatohepatitis because TgACAT2 produces more CEs than TgACAT1 and has broader fatty

---

**Table 12** Median and P25, P75 percentiles of the cell body, nucleus, and cytoplasm areas, and the nucleus/cell body area ratio of NADHd-p myentric neurons of the jejunum in pigs orally infected with oocysts of *T. gondii* type III (M7741 strain) and examined 30 days post inoculation (acc. to Odorizzi et al.[165]; with own modification)

| Cell components | NADHd-p | NADPHd-p |
|-----------------|---------|----------|
|                 | CG      | EG       | CG      | EG       |
| Cell body area  | 633.1   | 379.2    | 592.1   | 488.9    |
| (μm²)           | (475.0; 857.4) | (265.1; 557.5) | (270.3; 566.4) | |
| Nucleus area    | 144.8   | 101.7    | 126.1   | 94.1     |
| (μm²)           | (499.5; 207.5) | (130.4; 263.1) | (78.3; 120.0) | |
| Cytoplasm area  | 473.9   | 282.0    | 286.4   | 183.7    |
| (μm²)           | (342.3; 643.5) | (174.5; 441.8) | (183.7; 459.8) | |
| Nucleus/cell body area ratio | 0.24 | 0.26 | 0.24 | 0.24 |
|                  | (0.17; 0.31) | (0.21; 0.32) | (0.17; 0.32) | |

**Table 13** Degree of correlation between the cell body, nucleus and cytoplasm areas of NADPHd-p and NADHd-p myentric neurons of the jejunum in pigs orally infected with oocysts of *T. gondii* type III (M7741 strain) and examined 30 days post inoculation (acc. to Odorizzi et al.[165]; with own modification)

| Cell components          | NADPHd-p  | NADHd-p  |
|--------------------------|-----------|----------|
|                          | CG        | EG       | CG        | EG        |
| Cell body x nucleus      | 0.56      | 0.62     | 0.54      |           |
| (μm²)                    | (0.54; 0.73) | (0.62; 0.73) | | |
| Cell body x cytoplasm    | 0.93      | 0.98     | 0.98      |           |
| (μm²)                    | (0.91; 0.96) | (0.98; 0.98) | | |
| Nucleus x cytoplasm      | 0.29      | 0.48     | 0.4       |           |
| (μm²)                    | (0.27; 0.30) | (0.46; 0.51) | | |
Acid specificity[176]. T. gondii scavenges cholesterol from plasma low density lipoproteins (LDL) by rerouting host lysosomes to its PV, and further internalizes cholesterol using membrane-associated transport proteins[129]. Host LDL and fatty acids scavenged by the parasite can serve as ACAT activators, resulting in stimulation of CE synthesis and lipid droplet biogenesis in the body of the protozoan[171]. It was demonstrated that T. gondii strain with genetic ablation of ACAT2 exhibited large deposits of osmophilic material, likely lipids, both in the PV lumen and in the cytoplasm, thus reflecting gross lipid disorders as a consequence of perturbation of the balance between CEs and free cholesterol[171]. A similar disturbed balance can therefore occur during chronic latent T. gondii infection because in this biosynthesis both ACAT1 and ACAT2 enzyme activities in the infected host hepatocyte and intestine cells will be overlapping with the activity of TgACA T1 and TgACAT2, thus accumulating a significant surplus of their activities that finally lead to the development of steatohepatitis, as well as generation of foam cells (Table 14).

It was demonstrated in vitro that profusion of LDL in the culture medium lead to massive uptake of cholesterol by the parasite, suggestive of uncontrolled uptake of this lipid by T. gondii[171]. The parasite was competent to synthesize CEs using host cell-derived cholesterol and fatty acid, and the production was proportional to the amount of lipid taken up by the protozoan over the time[171,172]. It appeared that several FFAs were incorporated into parasite cholesteryl ester, suggestive of broad fatty acid specificity, but nearly twofold higher incorporation of palmitate into cholesteryl ester as compared with oleate, arachidonate, stearate, and linoleate was observed[171,176] (Tables 15 and 16). This preferential palmitate incorporation specificity by T. gondii acyl-CoA: diacylglycerol acyltransferase (TgDGAT1) has already been found also for triacylglycerol synthesis in the parasite[182], and TgDGAT1 is an integral membrane protein localized to the parasite cortical and perinuclear endoplasmic reticulum[176]. The protozoan was able to take up both oleate and diacylglycerol and incorporate them into the triacylglycerol fraction, and oleate was incorporated into diacylglycerol (Table 17).

Lige et al[171] suggested that the parasite scavenges LDL-cholesterol by uncontrolled uptake mechanisms, and engorges itself with cholesterol proportionally to the amount of the lipid in the environment. One may therefore speculate that this abnormality finally manifest histopathologically as steatohepatitis, and morphologically represent cholesterol ester-laden macrophages/foam cells, because the number and the size of lipid bodies in T. gondii vary between the different parasite developmental stages (tachyzoites, bradyzoites, oocysts), environmental conditions[171,181], infected cells/ tissues of the host, and intensity of oxidative stress associated with the infection. Moreover, proliferation of the parasite in the liver cells suppresses host cell autophagy in that organ[184] (as well as in other cells[185]), leading to abnormally high levels of cholesterol along with aberrant triglycerides deposition because of defective clearance of lipid droplets[186,187].

Interestingly, the activities of ACAT1 and ACAT2 can be stimulated in mutant parasites in response to accumulated free cholesterol. Concomitant to the increase in CEs content, the number and size of lipid bodies are dramatically enhanced in mutant parasites, probably to collect excess CE[188], and thereby providing a “safety sink” for toxic free cholesterol[171]. It should however be added that in healthy individuals lipid bodies found in the cytoplasm of a variety of cells, including leukocytes, macrophages, play an important role in modulating innate immune defense response

| Table 14 | Uptake of cholesterol by MEF ACAT1-/- cells transfected with TgACAT1 or TgACAT2, and incorporation into cholesteryl esters (acc. to Lige et al[170]; with own modification) |
|---|---|---|
| MEF ACAT1 transfected with | Cholesterol uptake (cpm x mg cell protein) | Cholesterol ester levels (cpm x mg cell protein) |
| Vector | 3991 ± 601 | ND |
| TgACAT1 | 4003 ± 510 | 898 ± 65 |
| TgACAT2 | 3785 ± 436 | 1514 ± 110 |

MEF ACAT1 were transfected with vector alone, or plasmids containing either TgACAT1 or TgACAT2. Cells were then incubated with [3H] cholesterol-LDL. Cholesterol uptake was monitored by scintillation counting. Cholesterol ester detection was performed by thin-layer chromatography analysis. The results are mean values ± SD from three incubations (*p < 0.01). MEF, mouse embryonic fibroblasts. ND, not detected. CPM, counts per minute.

| Table 15 | Comparison of free fatty acids (FFAs) uptake by T. gondii and CHO cells (acc. to Quittnat et al[176]; with own modification) |
|---|---|---|
| Oleate | Palmitate | Stearate | Linoleate | Arachidonate |
| T. gondii | 780 ± 99 | 1833 ± 105 | 810 ± 68 | 750 ± 91 | 767 ± 77 |
| CHO cells | 1220 ± 142 | 1156 ± 101 | 1467 ± 151 | 1550 ± 98 | 1058 ± 113 |

CHA, Chinese hamster ovary. Extracellular parasites or CHO cells were incubated for 1 h at 37°C with the indicated 0.3 mM radioactive FFAs. After washing, the total FFAs uptake was determined by measuring the cell-associated radioactivity and expressed in nmol per mg cell protein/h. Results are mean values ± SD from four separate experiments. Differences between values of the uptake of palmitate vs. other FFAs in T. gondii are statistically significant. *p < 0.005.

| Table 16 | Fatty acid specificity for triacylglyceride (TAG) synthesis in T. gondii (acc. to Quittnat et al[176]; with own modification) |
|---|---|---|---|---|---|
| Relative activities | [3H]Oleate | [3H]Oleate + palmitate | [3H]Oleate + stearate | [3H]Oleate + linoleate | [3H]Oleate + arachidonate |
| T. gondii | 1 | 0.18 | 0.69 | 0.5 | 0.61 |
| CHO cells | 1 | 0.52 | 0.62 | 0.35 | 0.59 |

CHO, Chinese hamster ovary. Extracellular T. gondii and CHO cells were incubated for 1 h at 37°C with 10 nM of radioactive oleate (~50,000 cpm per nmol) previously mixed with 0.3 mM of the indicated unlabeled FFAs to measure its incorporation into TAG. The production of TAG with oleic acid alone was 45,950 cpm per mg cell protein for T. gondii. The values expressed as relative activities, are means of three separate experiments.

| Table 17 | Lipid acquisition and substrate incorporation into n-acylglycerides of T. gondii (acc. to Quittnat et al[176]; with own modification) |
|---|---|---|---|
| Lipid uptake (cpm per mg cell protein) | Lipid synthesis (cpm per mg cell protein) |
| [3H]Oleate | 78589 ± 190 | 20444 ± 1874 |
| [3H]DAG | 59430 ± 3209 | 2960 ± 4705 |

DAG, diacylglycerol; TAG, triacylglycerol; cpm, counts per minute. Extracellular T. gondii were incubated for 1 h at 37°C with radioactive oleate or DAG before measurement of total lipid associated to parasites and lipid incorporation into DAG or TAG. The values are means ± SD of three separate experiments. Differences between DAG incorporation into TAG and TAG synthesis were statistically significant. *p < 0.005.

Hepatic Iron Overload in Steatohepatitis

Patients with nonalcoholic steatohepatitis and chronic viral hepatitis had increased serum iron levels and hepatic iron overload[189]. This finding is consistent with cytotoxic actions of NO produced by activated macrophages and a model of glucose-dependent...
Prandota J. Toxoplasmosis causes liver damage and cirrhosis

NO-mediated iron mobilization from cells proposed by Watts & Richardson[196,197]. They showed that NO intercepted iron before incorporation into ferritin and directly mobilized iron from ferritin in a glutathione-dependent manner. It should be emphasized that NO is produced in excess by the host cells as an important defense molecule directed against T. gondii infection[208,209,210]. On the other hand, iron is also necessary for multiplication of tachyzoites[212], and therefore overloading with iron is associated with persistent generation of a *circulus vitiosus*, detrimental for the host. Moreover, the excessive iron accumulation in liver causes hepatocellular injury and fibrosis[196-198], because reactive iron species produced in hepatocytes result in iron-dependent microsomal peroxidation of polyunsaturated fatty acids[199,200] and lipocyte activation/lipocyte fibrogenesis[192,201,202]. Similar abnormalities in iron and copper metabolism play a crucial role also in the pathogenesis of various neurodegenerative diseases[203,204], and this may further support an important role of *T. gondii* infection in development of these disturbances.

**FOAMY MACROPHAGES AND FOAMY COLITIS**

Characteristic foamy macrophages demonstrated in histopathological specimens are an important diagnostic factor in foamy colitis, and confirm mild and moderate course of that type of inflammation in children[205-207]. The induction of foamy macrophages packed with lipid bodies have been reported in several clinical pathologic states associated with chronic proinflammatory stimuli, including *T. gondii*[208] and another intracellular human pathogen, *Mycobacterium tuberculosis* infections[209]. Development of foamy colitis (microptic colitis) [205] may be due to oral infection with *T. gondii*. The parasite employs host low-density lipoproteins (LDL) receptor to acquire cholesterol[207] and diverts it for cholesteryl ester synthesis and storage in lipid bodies[197,199,210], leading to the formation of foam cells[208]. Macrophages convert into foam cells through a dysregulation in the balance between the influx and efflux of LDL particles (containing cholesterol, triacylglycerides and phospholipids) from the serum. Foamy macrophages are not only the product of an inflammatory response but amplify that response through production of PGE2 and leukotrienes[211,212], and appeared to be a key player in both persistent stimulating bacteria and contributing to development of human tuberculosis granuloma and cavitation[206]. Furthermore, in various types of cells, such as for example Kupffer cells, hepatocytes, vascular smooth muscle cells, the increased generation of PGE2 inhibited cytokine-stimulated NOS type 2 mRNA expression and NO synthesis in a concentration-dependent manner[211,212]. The effect of the prostaglandin was also associated with the number of macrophages[216]. All these disturbances could therefore affect innate and acquired immune responses of the host directed against oral prenatal or postnatal *T. gondii* infection, and result in generation of foamy macrophages and development of foamy colitis[213].

Frequent occurrence of a cryptogenic hypertransaminasemia in celiac patients (celiac hepatitis) reverting to normal after a few months of gluten withdrawal, as well as the presence of celiac disease in patients with primary biliary cirrhosis, autoimmune hepatitis, and primary sclerosing cholangitis[217], are in agreement with the above-presented reasoning[215]. Beneficial effects of diet with no gluten in patients with celiac disease may be explained by the fact that gluten induces a prouse intestinal cytokine response markedly predominated by IFN-γ (about 1000-fold in untreated disease)[215,216], and simultaneously there is also a significantly increased production of IFN-γ and other proinflammatory cytokines representing the host defense against concomitant latent *T. gondii* infection[214,215]. This overlapping excess of generation of interleukins in specific tissues of the host may finally be very destructive.

It must be emphasized that the presence of anti-tissue transaminase antibodies in patients with abnormal liver tests may not always solely suggest celiac disease[216,217]. Such comorbidities may be potentially harmful/beneficial for both humans and experimental animals because infecting pathogens can modulate inflammatory responses and final clinical outcomes[218,219,220]. Moreover, certain medicaments, such as for example disodium cromoglycate used in the patients with allergy, decrease activation of mast cells, and therefore attenuate parasite burden and decrease tissue lesions because its antihistaminic properties affect Th1/Th2 cytokine balance in the host[218,219]. Moreover, in animals infected with RH strain of the parasite this drug decreased *T. gondii* tachyzoite surface antigen 1 gene expression in spleen and liver tissues[221].

In summary, literature data suggest that latent chronic *T. gondii* infection plays an important role in triggering and maintaining disturbances of so far unexplained liver function and histopathologic abnormalities observed in many clinical entities and healthy subjects. It seems therefore that individuals with clinical symptoms of liver disease and associated laboratory irregularities that are not helpful in establishing proper diagnosis, should have tests for the parasite routinely performed and receive specific pharmacologic treatment. Hypocholesterolemic properties of citrus flavonoids, especially naringenin and hesperitin, may help in reducing activity and expression of ACAT1, ACAT2 and microsomal triglyceride transfer proteins, thus limiting harmful effects of triglyceride accumulation in the endoplasmic reticulum lumen of the host cells[220-222]. In addition, cytosteine protease inhibitors that block *T. gondii* microneme protein secretion, glding motility, and host cell invasion may represent potent anti-parasitic agents capable of curing infections in vivo, including the chick embryo model of toxoplasmosis[220,222]. Moreover, the parasite cathepsin B and L proteins may represent potential novel DNA vaccine antigens against toxoplasmosis[223], especially that cathepsin B has recently been identified as β-secretase for the production of β-amyloid peptides that accumulate in Alzheimer’s disease[224] (this is in line with the above-mentioned suggestion that similar biochemical processes participated in the generation of amyloid present in MDBs). Interestingly, phytoxin (an antiepileptic drug) and cyclosporine A (an immunosuppressant) suppress the expression and activity of cathepsin L and B in cultured gingival fibroblasts[225,226]. Moreover, these two drugs stimulated TGF-β and cathepsin B production and inhibited expression of matrix metalloproteinase-1 by fibroblasts[226,227]. These are very important findings because they represent a novel mechanism of action of these two medicaments, and the above-presented reasoning is supported by the fact that chronic *T. gondii* infection was suggested to be the etiologic agent in cryptogenic epilepsyc[228,219]. Recently, two groups[226,227] published clinical data supporting my suggestions that toxoplasmosis is a critical risk factor responsible for development of liver cirrhosis. In addition, an important role of *T. gondii* in the generation of nonalcoholic fatty liver disease has been suggested in a population-based studies[227]. The increasing prevalence of unexplained liver abnormalities[221], and overweight and obesity growing dramatically all over the world[228,246], are well in line with wide geographical distribution of the parasite. High burden of liver diseases and low awareness of toxoplasmosis amongst healthcare providers reported even in the United States require more effective public health actions[245,246].
REFERENCES

1. Torgerson R, Mastroiacovo P. The global burden of congenital toxoplasmosis: a systematic review. *Bull World Health Organ* 2013; 91(7): 501-508. [PMID: 23825877]; [DOI: 10.2471/BLT.2.111732]

2. Furtado JM, Smith JR, Belfort R Jr, Gattey D, Winthrop KL. Toxoplasmosis: A global threat. *J Glob Infect Dis* 2011; 3(3): 281-284. [PMID: 2187602]; [DOI: 10.4103/0974-777X.83536]

3. Flegr J, Prandota J, Sovickova M, Izraili ZH. Toxoplasmosis -- a global threat. Correlation of latent toxoplasmosis with specific diseases burden in a set of 88 countries. *PLOS ONE* 2014; 9(3): e90203. [PMID: 24662942]; [DOI: 10.1371/journal.pone.0090203]

4. Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet* 2004; 363(9425): 1965-1976. [PMID: 15194258]; [DOI: 10.1016/S0140-6736(04)16142-X]

5. Halonen SK, Weiss LM. Toxoplasmosis. *Handb Clin Neurol.* 2013; 114: 125-145. [PMID: 23829964]; [DOI: 10.1016/B978-0-444-440008-X]

6. McLeod R, Van Tubbergen C, Montoya JG, Petersen E. Human Toxoplasma Infection. In: Weiss LM, Kim K (eds). Toxoplasmosis: A global threat. Correlation of latent toxoplasmosis with specific diseases burden in a set of 88 countries. *PLOS ONE* 2014; 9(3): e90203. [PMID: 24662942]; [DOI: 10.1371/journal.pone.0090203]

7. Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet* 2004; 363(9425): 1965-1976. [PMID: 15194258]; [DOI: 10.1016/S0140-6736(04)16142-X]

8. McLeod R, Van Tubbergen C, Montoya JG, Petersen E. Human Toxoplasma Infection. In: Weiss LM, Kim K (eds). Toxoplasmosis: A global threat. Correlation of latent toxoplasmosis with specific diseases burden in a set of 88 countries. *PLOS ONE* 2014; 9(3): e90203. [PMID: 24662942]; [DOI: 10.1371/journal.pone.0090203]

9. Halonen SK, Weiss LM. Toxoplasmosis. *Handb Clin Neurol.* 2013; 114: 125-145. [PMID: 23829964]; [DOI: 10.1016/B978-0-444-440008-X]

10. McLeod R, Van Tubbergen C, Montoya JG, Petersen E. Human Toxoplasma Infection. In: Weiss LM, Kim K (eds). Toxoplasmosis: A global threat. Correlation of latent toxoplasmosis with specific diseases burden in a set of 88 countries. *PLOS ONE* 2014; 9(3): e90203. [PMID: 24662942]; [DOI: 10.1371/journal.pone.0090203]

11. Das UN. Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation. *Med Sci Monit* 2007; 13(12): RA214-RA221. [PMID: 18049445]

12. Das UN. Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation. *Ann Hepatol* 2012; 11(3): 409-411. [PMID: 22481463]

13. Lampon N, Hermina-Cadahia EF, Riveiro A, Tutor JC. Association between butyrylcholinesterase activity and low-grade systemic inflammation. *Ann Hepatol* 2012; 11(3): 356-363. [PMID: 22481455]

14. Rao M, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease. *Med Hypotheses* 2007; 69(6): 1272-1276. [PMID: 17553629]; [DOI: 10.1016/j.mehy.2007.03.032]

15. Prandota J. Toxoplasmosis causes liver damage and cirrhosis.
Prandota J. Toxoplasmosis causes liver damage and cirrhosis.
Prandota J. Toxoplasma causes liver damage and cirrhosis

99. Chen W, Sylstad U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat shock protein: a danger signal to the innate immune system. J Immunol 1999; 162(6): 3212-3219. [PMID: 10092772]

100. Flohe SB, Brüggemann J, Lendemann S, Nikulina M, Meierhoff G, Flohe S, Kolb H. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 2003; 170(5): 2340-2348. [PMID: 12594256]; [DOI: 10.4049/jimmunol.170.5.2340]

101. Cohen-Sfady M, Nussbaum G, Pavner-Fischer M, Mor F, Carmi P, Zain-Nazorov A, et al. Heat shock protein 60 activates B cells via the TLR4-Myl08 pathway. J Immunol 2005; 175(6): 3594-3602. [PMID: 16148103]; [DOI: 10.4049/jimmunol.175.6.3594]

102. Twezer-Zaks N, Doron-Libner A, Weiss P, Ben-Horin S, Barshack I, Lidor M, et al. Familial Mediterranean fever and cryptogenic cirrhosis. Medicine (Baltimore) 2007; 86(6): 355-362. [PMID: 18004180]; [DOI: 10.1097/MD.0b013e31815bed05]

103. Kastner DL. Hereditary periodic fever syndromes. Hematol Am Soc Hematol Educ Program 2005; 74-81. [PMID: 16384362]

104. Chae JJ, Komarow HO, Cheng J, Wood G, Raben N, Liu P, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11(3): 591-604. [PMID: 12667444]; [DOI: 10.1016/S0979-2765(03)00056-X]

105. Mansfield E, Chae JJ, Komarow HO, Broz TM, Frucht DM, Askentievich I, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with h actin filaments. Blood 2001; 98(3): 851-859. [PMID: 11468188]; [DOI: 10.1182/blood.V98.3.851]

106. Prandota J. Idiopathic intracranial hypertension may be caused by reactivation of latent cerebral toxoplasmosis. J Neurovirol 2009; 19(10): 1655-1692. [PMID: 19922380]; [DOI: 10.1080/0274008200480004]

107. Prandota J. Mollaret meningitis may be caused by reactivation of latent cerebral toxoplasmosis. J Neurol Neurosurg Psychiatry 2005; 74-81. [PMID: 16304362]; [DOI: 10.1016/S0168-8278(01)00272-6]

108. Lu CY, Lai SC. Induction of matrix metalloproteinase-2 and -9 via Erk1/2-NF-κB pathway in human astroglia infected with Toxoplasma gondii. Acta Tropica 2013; 127(1): 14-20. [PMID: 23517828]; [DOI: 10.1016/j.actatropica.2013.03.004]

109. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278(1): 379-463. [PMID: 21087457]; [DOI: 10.1111/j.1742-4658.2010.07919.x]

110. Prandota J. Critical role of latent chronic Toxoplasma gondii infection in triggering, development and persistence of autoimmune diseases. Int J Neurosci 2018; 4(1): 379-463. [PMID: 10.17554/ijs.2013-5611.2018.04.79]

111. Borthwick LA, Wynn TA, Fisher AJ. Cytokine mediated tissue inactivation. Cell 2013; 152(4): 180-183. [PMID: 23592154]; [DOI: 10.1182/jimmunol.1003917]

112. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46(4): 443-446. [PMID: 10716665]; [DOI: 10.1136/gut.46.4.443]

113. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122(5): 1525-1528. [PMID: 11984538]; [DOI: 10.1053/gast.2002.33367]

114. Junquero DC, Scott-Burden T, Schini VB, Vanhoutte PM. Inhibition of cytokine-induced nitric oxide production by transforming growth factor-β1 in human smooth muscle cells. J Physiol 1992; 454: 451-465. [PMID: 1282159]

115. Durante W, Peyton KJ, Schafer AJ. Platelet-derived growth factor stimulates heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19(11): 2666-2672. [PMID: 10.1161/01.HYP.100.3917]
132. Prandota J. Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in non-human immunodeficiency virus-infected subjects with no lymphadenopathy. The parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches. Am J Ther 2007; 14(3): 63-105. [PMID: 17303977]; [DOI: 10.1097/01.mji.0000208272.42379.aa]

133. Prandota J. Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation. Int J Neurosci 2010; 120(2): 81-87. [PMID: 20199196]; [DOI: 10.3109/00207450903458647]

134. Spear W, Chan D, Copps I, Johnson RS, Giacca A, Blader JJ. The host cell transcription factor hypoxia inducible factor 1 is required for Toxoplasma gondii growth and survival at physiological oxygen levels. Cell Microbiol 2006; 8(2): 339-352. [PMID: 16441433]; [DOI: 10.1111/j.1462-5822.2005.00628.x]

135. Chumptazi BF, Simon JJ, Polack B, Peyron F, Picot S, Ricard J, et al. Human platelet inhibition of Toxoplasma gondii growth. Clin Exp Immunol 1998; 111(2): 325-333. [PMID: 9486399]; [DOI: 10.1046/j.1365-2249.1998.00499.x]

136. Yong EC, Chi EY, Fritsche TR, Henderson WR. Human platelet-mediated cytotoxicity against Toxoplasma gondii: Role of thromboxane. J Exp Med 1991; 173(1): 65-78. [PMID: 1898664]

137. Henderson WR Jr, Rashed M, Yong EC, Fritsche TR, Chiang GK. Toxoplasma gondii stimulates the release of 13- and 8-hydroxyoctadecadienoic acids by human platelets. Biochemistry 1992; 31(23): 5356-5362. [PMID: 1606159]

138. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Den H. Ballooned hepatocytes in steatohepatitis: The value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 48(5): 821-828. [PMID: 18329127]; [DOI: 10.1016/j.jhep.2008.01.026]

139. Denk H. Role of cytochrome P450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology 1992; 16(4): 992-996. [PMID: 1398507]

140. French SW, Nash J, Shitabata P, Kachi K, Hara C, Chedid A, et al. Are the Mallory bodies and the intracellular hyaline bodies in alcoholic liver disease the same as in nonalcoholic fatty liver disease? Semin Liver Dis 2004; 24(3): 273-287. [PMID: 15349805]; [DOI: 10.1055/s-2004-832940]

141. Schaff Z, Lapis K. Fine structure of hepatocytes during the hypertrophy of the myenteric plexus of Rattus norvegicus. Exp Cell Res 1987; 175(3): 151-169. [PMID: 3151973]; [DOI: 10.1016/j.yexcr.007.04.024]

142. Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, et al. From Mallory to Mallory-Denk bodies: what, how, why? Exp Cell Res 2007; 313(10): 2033-2049. [PMID: 17531973]; [DOI: 10.1016/j.yexcr.007.04.024]

143. Denk H, Stumptner C, Fuchsbieler A, Müller T, Farr G, Müller W, et al. Are the Mallory bodies and the intracellular hyaline bodies in neoplastic and nonneoplastic hepatocellular carcinomas related? J Pathol 2000; 192(5): 653-661. [PMID: 16477590]; [DOI: 10.1002/path.1496]

144. Zatloukal K, Stumptner C, Fuchsbieler A, Fickert P, Lackner C, Trauner M, et al. The keratin cytoskeleton in liver diseases. J Pathol 2004; 204(4): 367-376. [PMID: 15495250]; [DOI: 10.1002/path.1649]

145. Yang JF, Yue HP, Hou YY, Liu ZS, Rao RX, He YX, et al. Acute infection of Toxoplasma gondii affects the level of oxygen free radicals in serum and testes of mice. Zhongguo Ji Sheng Chong Bing Za Zhi 2010; 20(5): 364-367. [PMID: 21351550]

146. Yazar S, Kilic E, Saraymen R, Sahin I. Serum malondialdehyde levels in Toxoplasma seropositive patients. Ann Saudi Med 2003; 23(6): 413-415. [PMID: 16868383]; [DOI: 10.5144/0256-4947.2003.413]

147. Al Kennawy ER, Al Badrany SM. Pathological study of the capability of Toxoplasma gondii to induce oxidative stress and initiation a primary lesion of atherosclerosis experimentally in broiler chickens. J Anim Vet Adv 2007; 6(8): 938-942. [DOI: javaa.2007.938.942]
Ehrenman K, Sehgal A, Lige B, Stedman TT, Joiner KA, Ann Trop Med Parasitol 2011; 108(1): 67-74. [PMID: 21499751]; [DOI: 10.1007/s13592-011-0060-0]

Mayer RJ, Lowe J, Lennox G, Doherty F, Landon M, Intermediate filament organization: a new thread in the understanding of chronic neurodegenerative diseases. Prog Clin Biol Res 2003; 317: 809-818. [PMID: 2557642]

Lige B, Sampels V, Coppens I. Characterization of a second sterol-esterifying enzyme in Toxoplasma highlights the importance of cholesterol storage pathways for the parasite. Mol Microbiol 2013; 87(5): 951-967. [PMID: 23374239]; [DOI: 10.1111/mmi.12142]

Coppens I, Joiner KA. Host but not parasite cholesterol controls Toxoplasma cell entry by modulating organelle discharge. Mol Biol Cell 2003; 14(9): 3804-3820. [PMID: 12972565]; [DOI: 10.1091/mbc.e02-12-0830]

Leon C, Hill JS, Wasan KM. Potential role of acyl-coenzyme A:cholesterol acyltransferase. A neutrophil chemoattractant by rat hepatocytes metabolizing ethanol. J Biol Chem 2000; 275(36): 28083-28092. [PMID: 10846185]; [DOI: 10.1074/jbc.M003927200]

Buhman KK, Accad M, Novak S, Choi RS, Wong JS, Hamilton RL, et al. Resistance to diet-induced hypercholesterolemia and gallstone in ACAT2-deficient mice. Nat Med 2000; 6(12): 1341-1347. [PMID: 11001188]; [DOI: 10.1038/82153]

Quintat N, Fiskishawa Y, Stedman T, Voelker DR, Choi JY, Zahn MM, et al. On the biogenesis of lipid bodies in ancient eukaryotes: synthesis of triacylglycerols by a Toxoplasma DGAT1-related enzyme. Mol Biochem Parasitol 2004; 138(1): 107-122. [PMID: 15500922]; [DOI: 10.1016/j.molbiopara.2004.08.004]

Murphy DJ, Vance J. Mechanism of lipid-body formation. Trends Biochem Sci 1999; 24(3): 109-115. [PMID: 10203758]

Nishikawa Y, Quintat F, Stedman TT, Voelker DR, Choi JY, Zahn M, et al. Host cells lipid control cholesterol ester synthesis and storage in intracellular Toxoplasma. Cell Microbiol 2005; 7(6): 849-867. [PMID: 15888087]; [DOI: 10.1111/j.1464-5822.2005.00518.x]

Chang TY, Li BL, Chang CC, Urano Y. Acyl-coenzyme A:cholesterol acyltransferases. Am J Physiol Endocrinol Metab 2009; 297(1): E1-E9. [PMID: 19141679]; [DOI: 10.1152/ajpendo.90926.2008]

Ehrenman K, Sehgal A, Lige B, Stedman TT, Joiner KA, Coppens I. Novel roles for ATP-binding cassette G transporters in lipid redistribution in Toxoplasma. Mol Microbiol 2010; 76(5): 1232-1249. [PMID: 20487267]; [DOI: 10.1111/j.1365-2958.2010.07169.x]

Sonda S, Ting LM, Novak S, Kim K, Maher JJ, Farese RV Jr, Ernst JD. Cholesterol esterification by host and parasite is essential for optimal proliferation of Toxoplasma gondii. J Biol Chem 2001; 276(37): 34434-34440. [PMID: 11457847]; [DOI: 10.1074/jbc.M105025200]

Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1995; 92(22): 13018-13023. [PMID: 7989033]

Dubey JP. Advances in the life cycle of Toxoplasma gondii. Int J Parasitol 1998; 28(7): 1019-1024. [PMID: 9724872]

Lee YJ, Song HO, Lee HY, Ryu JS, Ahn MH. Proliferation of Toxoplasma gondii suppresses host cell autophagy. Korean J Parasitol 2013; 51(3): 279-287. [PMID: 23864738]; [DOI: 10.3347/kjp.2013.51.3.279]

Muniz-Feliciano L, Van Grol J, Portillo JAC, Liew L, Liu B, Carlin CR, et al. Toxoplasma gondii-induced activation of EGFR prevents autophagy: protein-induced killing of the parasite. PLoS Pathogen 2013; 9(12): e1003809. [PMID: 24367261]; [DOI: 10.1371/journal.ppat.1003809]

Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature 2009; 458(7242): 1131-1136. [PMID: 19393967]; [DOI: 10.1038/nature07976]

Dong H, Czaja MJ. Regulation of lipid droplets by autophagy. Trends Endocrinol Metab 2011; 22(6): 234-240. [PMID: 21419642]; [DOI: 10.1016/j.tem.2011.02.003]

Lige B, Romano JD, Bandaru WR, Ehrenman K, Levitskaya K, Sampels V, et al. Deficiency of a Niemann-Pick, type C1-related protein in Toxoplasma is associated with multiple lipidoses and increased pathogenicity. PLoS Pathogens 2011; 7(12): e1002410. [PMID: 22341417]; [DOI: 10.1371/journal.ppat.1002410]

D’Avila H, Maya-Monteiro CM, Bozza PT. Lipid bodies in innate immune response to bacterial and parasite infections. Int Immunopharmacol 2008; 8(10): 1308-1315. [PMID: 18687292]; [DOI: 10.1016/j.intimp.2008.01.035]

Melo RC, Fabrino DL, Dias FF, Parreira GG. Lipid bodies: structural markers of inflammatory macrophages in innate immunity. Inflamm Res 2006; 55(8): 342-348. [PMID: 16977381]; [DOI: 10.1007/s00011-006-5205-0]

Bozza PT, Melo RCN, Bandeira-Melo C. Leucocyte lipid bodies regulation and function: Contribution to allergy and host defense. Pharmacol Ther 2007; 113(1): 30-49. [PMID: 16945418]; [DOI: 10.1016/j.pharmthera.2006.06.006]

Uraz S, Aygunes Sonias A, Ozbay G. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Digestive Dis Sci 2005; 50(5): 964-969. [PMID: 15906776]; [DOI: 10.1007/s10620-005-2627-x]

Watts RN, Richardson DR. The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. Eur J Biochem 2002; 269(14): 3383-3392. [PMID: 12135476]; [DOI: 10.1046/j.1432-1032.2002.02987.x]

Liew FY. The role of nitric oxide in parasitic diseases. Ann Trop Dis Parasitol 1993; 87: 637 -642. [PMID: 7510100]; [DOI: 10.1080/00034908.1993.11812822]

Oswald IP, Wynn TA, Sher A, James SL. NO as a effector molecule of parasite killing: modulatori of its synthesis by cytokines. Comp Biochem Physiol Toxicol Endocurial 1994; 108(1): 11-15. [PMID: 7502338]

Halterantz R, Bissell DM, Roll FJ. Iron mediates production of a neutrophil chemottractant by rat hepatocytes metabolizing ethanol. J C/in Invest 1991; 87(1): 45-49. [PMID: 2985111]; [DOI: 10.1172/JCI114999]

George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114(2): 311-318. [PMID: 9453491]
Prandota J. Toxoplasmosis causes liver damage and cirrhosis

230. Teo CF, Zhou XW, Bogo M, Carruthers VB. Cysteine protease inhibitors block Toxoplasmosis gondii microneme secretion and cell invasion. *Antimicrob Agents Chemother* 2007; 51(2): 679-688. [PMID: 17145790]; [DOI: 10.1128/AAC.01059-06]

231. Dou Z, Carruthers VB. Cystein protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion. *Antimicrob Agents Chemother* 2007; 51(2): 679-688. [PMID: 17145790]; [DOI: 10.1128/AAC.01059-06]

232. Que X, Engel JC, Ferguson D, Sun M, Bai Y, et al. Toxoplasma gondii cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii. *J Biol Chem* 2007; 282(7): 4994-5003. [PMID: 17164247]; [DOI: 10.1074/jbc.M606764200]

233. Zhao G, Zhou A, Lv G, Meng M, Sun M, Bai Y, et al. Toxoplasma gondii cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii. *J Biol Chem* 2007; 282(7): 4994-5003. [PMID: 17164247]; [DOI: 10.1074/jbc.M606764200]

234. Hook V, Funkelstein L, Wegrzyn J, Bark S, Kindy M, Hook G. Cysteine cathepsins in the secretory vesicle produce active peptides: cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer’s disease. *Biochim Biophys Acta* 2012; 1824(1): 89-104. [PMID: 21925292]; [DOI: 10.1016/j.bbapap.2011.08.015]

235. Yamaguchi M, Naruishi K, Yamada-Naruishi H, Omori K, Nashimura F, Takashiba S. Long-term cyclosporine A exposure suppresses cathepsin-B and -L activity in gingival fibroblasts. *J Periodont Res* 2004; 39(5): 320-326. [PMID: 15324353]; [DOI: 10.1111/j.1600-0765.2004.00746.x]

236. Yamada H, Nishimura F, Naruishi K, Chou HH, Takashiba S, Albright GM, et al. Phenytoin and cyclosporine A suppress the expression of MMP-1, TIMP-1, and cathepsin B in cultured gingival fibroblasts. *J Periodontol* 2000; 71(6): 955-960. [PMID: 10914799]; [DOI: 10.1902/jop.2000.71.6.955]

237. Vahabi S, Salman BN, Rezazadeh F, Namdari M. Effects of cyclosporine and phenytoin on biomarker expressions in gingival fibroblasts of children and adults: an in vitro study. *J Basic Clin Physiol Pharmacol* 2014; 25(2): 167-173. [PMID: 23907422]; [DOI: 10.1515/bcp-2013-0003]

238. Ngougou EB, Bhalla D, Ngogbe A, Darde ML, Preux PM. Toxoplasmosis and epilepsy -- systematic review and meta-analysis. *PLoS Negl Trop Dis* 2015; 9(2): e0003525. [PMID: 25695802]; [DOI: 10.1371/journal.pntd.0003525]

239. Stommel EW, Seguin R, Thadani VM, Schwartzman JD, Gilbert K, Ryan KA, et al. Cryptogenic epilepsy: an infectious etiology? *Epilepsia* 2001; 42(3): 436-438. [PMID: 11442166]; [DOI: 10.1046/j.1528-1157.2001.25500.x]

240. El-Henawy AE, Razik M, Zakaria S, El Hammond M, Soudy N, Azab MS. Is toxoplasmosis a potential risk factor for liver cirrhosis. *Asian Pacific J Trop Med* 2015; 8(10): 784-791. [PMID: 26522292]; [DOI: 10.1016/j.apjtm.2015.09.003]

241. El Sayed NM, Ramadan ME, Ramadan ME. Toxoplasma gondii infection and chronic liver diseases: evidence of an association. *Trop Med Infect Dis* 2016; 1(1): 7. [PMID: 30270858]; [DOI: 10.3390/tropicalmed1010007]

242. Huang J, Hang H, Liu S, Wang M, Wan B, Velani B, et al. Is toxoplasmosis a potential risk factor for liver disease? -- a population-based study. *BMC Infect Dis* 2018; 18: 629. [PMID: 30522446]; [DOI: 10.1186/s12879-018-3547-1]

243. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, Lopez R, Akars Z, Zain N, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data. *Am J Gastroenterol* 2017; 112(4): 581-587. [PMID: 28195177]; [DOI: 10.1038/ajg.2017.5]

244. Ng M, Fleming T, Robinzon M, Thomson B, Graetz N, Margono C, et al. Global, regional and national prevalence of overweight and obesity in children and adults 1980–2013: a systematic analysis. *Lancet* 2014; 384(9945): 766-781. [PMID: 24880830]; [DOI: 10.1016/S0140-6736(14)60460-8]

245. Asrani SK, Devabhaktuni H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019; 70(1): 151-171. [PMID: 30266282]; [DOI: 10.1016/j.jhep.2018.09.014]

246. Ben-Hararri RR, Connolly MP. High burden and low awareness of toxoplasmosis in the United States. *Postgrad Med.* 2019 Mar; 131(2): 103-108. [PMID: 30638425]; [DOI: 10.10180/00325481.2019.1568792]